- Sunshine Biopharma (SBFM, Financial) launches Everolimus in Canada through its subsidiary Nora Pharma Inc.
- The global Everolimus market is valued at $2.5 billion in 2023, projected to grow to $4.8 billion by 2032.
- The Canadian market represents 2.2% of the global market, growing at a CAGR of 6.4%.
Sunshine Biopharma Inc. (SBFM), a pharmaceutical company focusing on oncology and antiviral treatments, has announced the launch of Everolimus in the Canadian market through its wholly-owned subsidiary, Nora Pharma Inc. Everolimus is a generic equivalent of Afinitor® and is prescribed for treating various conditions, including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.
The drug is available in dosages of 2.5 mg, 5 mg, and 10 mg, packaged in 30-tablet blister packs. The global market for Everolimus was valued at $2.5 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.1%, reaching approximately $4.8 billion by 2032. The Canadian market segment constitutes about 2.2% of the global market, with a growth rate of 6.4% CAGR.
According to Dr. Steve Slilaty, CEO of Sunshine Biopharma, the company continues to expand its presence in the pharmaceutical industry by investing in innovative technologies and strategic partnerships to deliver impactful solutions to patients. Sunshine Biopharma plans to introduce more than 15 additional drugs, including NIOPEG®, a biosimilar of NEULASTA®, by the end of 2025.
